Valuation: Dogwood Therapeutics, Inc.

Market Cap 50.11M 43.8M 40.26M 37.52M 71.17M 4.77B 72.25M 483M 188M 2.35B 188M 184M 8.08B P/E 2026 *
-2.55x
P/E 2027 * -2.28x
Enterprise Value 50.11M 43.8M 40.26M 37.52M 71.17M 4.77B 72.25M 483M 188M 2.35B 188M 184M 8.08B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
26.64%
Yield 2026 *
-
Yield 2027 * -
1 day-0.67%
1 week-9.70%
Current month-7.45%
1 month-7.45%
3 months-29.38%
6 months-64.86%
Current year-64.18%
1 week 1.45
Extreme 1.45
1.8
1 month 1.41
Extreme 1.41
1.8
Current year 1.28
Extreme 1.28
4.34
1 year 1.28
Extreme 1.28
9.5
3 years 1.28
Extreme 1.28
60.5
5 years 1.28
Extreme 1.28
227.77
10 years 1.28
Extreme 1.28
417.75
Date Insider Type Main position Quantity % Market Cap.
06-15Free

Director

16,800 0.0505%
06-15Free

Director

16,800 0.0505%
06-15Free

Director

16,800 0.0505%
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%-9.70%-68.96%-95.62% 50.11M
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
Average +2.52%+7.78%+42.28%+120.96% 24.55B
Weighted average by Cap. +2.46%+6.47%+59.03%+137.66%

Financials

2026 *2027 *
Net sales - -
Net income -19.79M -17.3M -15.9M -14.82M -28.1M -1.88B -28.53M -191M -74.19M -926M -74.27M -72.68M -3.19B -24.52M -21.43M -19.7M -18.36M -34.83M -2.33B -35.35M -236M -91.93M -1.15B -92.03M -90.06M -3.95B
Net Debt - -
Logo Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Employees
8
Date Price Change Volume
26-07-02 US$1.490 -0.67% 107,758
26-07-01 US$1.500 -6.83% 135,901
26-06-30 US$1.610 -9.55% 53,528
26-06-29 US$1.780 +7.88% 55,918
26-06-26 US$1.650 +11.49% 205,731
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.490USD
Average target price
14.00USD
Spread / Average Target
+839.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DWTX Stock